Products - Prostate cancer | Topic | NICE

Showing 12 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer (TA1110)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 November 2025
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA1109)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 November 2025
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
11 February 2026
Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
25 March 2026
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
30 September 2026
Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
7 April 2027
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)
Status:
In development
Programme:
Medical technologies guidance
Expected publication date:
TBC
Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate cancer after abiraterone acetate [TSID12239]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Prostate cancer: diagnosis and management (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Digital AI tools in histopathology (breast and prostate cancer)
Status:
Awaiting development
Programme:
Health technology evaluation
Expected publication date:
TBC
Artificial intelligence (AI) technologies to help detect prostate cancer on multiparametric (mp) MRI
Status:
In development
Programme:
Health technology evaluation
Expected publication date:
TBC